A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis

New England Journal of Medicine

Volumn 350, Issue 3, 2004, Pages 249-258

  Garcia, Héctor H ^a,f   Pretell, E Javier ^a   Gilman, Robert H ^c   Martinez, S Manuel ^a   Moulton, Lawrence H ^c   Del Brutto, Oscar H ^d   Herrera, Genaro ^a   Evans, Carlton A W ^a,c,e   Gonzalez, Armando E ^b,c  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS   (Peru)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HOSPITAL CLÍNICA KENNEDY   (Ecuador)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTICONVULSIVE AGENT; ANTIPARASITIC AGENT; DEXAMETHASONE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GRAND MAL SEIZURE; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROCYSTICERCOSIS; NEUROLOGIC DISEASE; PARESIS; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALBENDAZOLE; ANTI-INFLAMMATORY AGENTS; ANTICESTODAL AGENTS; ANTICONVULSANTS; BRAIN; BRAIN DISEASES; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRANULOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROCYSTICERCOSIS; SEIZURES;

EID: 0346093858     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa031294     Document Type: Article

References (35)

1. Garcia HH, Del Brutto OH. Taenia solium cysticercosis. Infect Dis Clin North Am 2000;14:97-119.
2. Bern C, Garcia HH, Evans C, et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis 1999;29:1203-9.
3. Schantz PM, Wilkins PP, Tsang VCW. Immigrants, imaging and immunoblots: the emergence of neurocysticercosis as a significant public health problem. In: Scheld WM, Craig WA, Hughes JM, eds. Emerging infections 2. Washington, D.C.: ASM Press, 1998:213-41.
4. Ong S, Talan DA, Moran GJ, et al. Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments. Emerg Infect Dis 2002;8:608-13.
5. Dixon HB, Lipscomb FM. Cysticercosis: an analysis and follow-up of 450 cases. In: office HMsS, ed. Special report series. Vol. 299. London: Medical Research Council, 1961.
6. Del Brutto OH, Sotelo J. Neurocysticercosis: an update. Rev Infect Dis 1988;10:1075-87.
7. Carpio A. Neurocysticercosis: an update. Lancet Infect Dis 2002;2:751-62.
8. Garcia HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-56.
9. Sotelo J, del Brutto OH, Penagos P, et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990;237:69-72.
10. Gonzalez AE, Garcia HH, Gilman RH, et al. Treatment of porcine cysticercosis with albendazole. Am J Trop Med Hyg 1995;53:571-4.
11. Vazquez V, Sotelo J. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med 1992;327:696-701.
12. Del Brutto OH, Santibanez R, Noboa CA, Aguirre R, Diaz E, Alarcon TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992;42:389-92.
13. Carpio A, Santillan F, Leon P, Flores C, Hauser WA. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 1995;155:1982-8.
14. Spina-Franca A, Nobrega JP, Livramento JA, Machado LR. Administration of praziquantel in neurocysticercosis. Tropenmed Parasitol 1982;33:1-4.
15. Friedman J, Mates S. Praziquantel therapy for cysticercosis. Arch Neurol 1983;40:257.
16. McCormick GF. Praziquantel therapy for cysticercosis. Arch Neurol 1983;40:258.
17. Goldberg MA. Praziquantel for cysticercosis of the brain parenchyma. N Engl J Med 1984;311:733-4.
18. Kramer LD, Locke GE, Byrd SE, Daryabagi J. Cerebral cysticercosis: documentation of natural history with CT. Radiology 1989;171:459-62. [Erratum, Radiology 1989;173:286.]
19. Kramer LD, Locke GE, Byrd SE, Daryabagi J. Cerebral cysticercosis: documentation of natural history with CT. Radiology 1989;171:459-62. [Erratum, Radiology 1989;173:286.]
20. Kramer LD. Medical treatment of cysticercosis - ineffective. Arch Neurol 1995;52:101-2.
21. Miller B, Grinnell V, Goldberg MA, Heiner D. Spontaneous radiographic disappearance of cerebral cysticercosis: three cases. Neurology 1983;33:1377-9.
22. Moodley M, Moosa A. Treatment of neurocysticercosis: is praziquantel the new hope? Lancet 1989;1:262-3.
23. Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 1989;159:50-9.
24. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
25. Sirven JI. Classifying seizures and epilepsy: a synopsis. Semin Neurol 2002;22:237-46.
26. Wyllie E, ed. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore: Williams & Wilkins, 1997.
27. Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 2002;59:1730-4.
28. Robles C, Chavarria Chavarria M. Presentación de un caso clínico de cisticercosis cerebral tratado médicamente con un nuevo fármaco: praziquantel. Salud Publica Mex 1979;21:603-18.
29. Botero D, Castano S. Treatment of cysticercosis with praziquantel in Colombia. Am J Trop Med Hyg 1982;31:811-21.
30. Gonzales AE, Garcia HH, Gilman RH, et al. Effective, single-dose treatment of porcine cysticercosis with oxfendazole. Am J Trop Med Hyg 1996;54:391-4.
31. Garcia HH, Gilman RH, Horton J, et al. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Neurology 1997;48:1421-7.
32. Garcia HH, Gonzalez AE, Evans CAW, Gilman RH, Cysticercosis Working Group in Peru. Taenia solium cysticercosis. Lancet 2003;362:547-56.
33. Singh G. Neurocysticercosis in South-Central America and the Indian subcontinent: a comparative evaluation. Arq Neuropsiquiatr 1997;55:349-56.
34. Proafio JV, Madrazo I, Avelar F, López-Félix B, Díaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001;345:879-85.
35. Del Brutto OH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994;44:1706-9.